- Why You And Your Pooch Share Similar Reactions to Life
- How to Gauge Your Personal Risk For a Hernia
- Journalists Talk Medicaid Work Mandate in Georgia and Wage Garnishment Bill in Colorado
- How NYU Langone built 1 of the nation’s fastest-growing GI divisions
- BCBS study: Hospital AI billing tools may be driving up healthcare costs by billions
- The transition gap: How RCA is using recovery housing to prevent relapse
- CMS moves forward with 3rd round of Medicare drug negotiations
- Kroger pharmacies add Zepbound KwikPen
- Nurses navigate AI-generated health information at bedside
- Louisiana senator resumes push to repeal water fluoridation program
- HCA’s highest-earning executives in 2025
- HCA’s highest-earning executives in 2025
- CHS Alabama hospital CEO heads to Florida
- RWJBarnabas New Jersey hospital taps new COO
- Why some health system CEOs are opting out of cross-market expansion
- Stanford Health Care leader to advise agentic AI startup
- Piedmont, Encompass tap CEO for planned Georgia hospital
- Inside Virginia’s 1st ‘tri-accredited’ bariatric surgery center
- The red flags DSOs can’t afford to ignore
- About 82% of public Medicare Advantage rate notice comments tied to ‘dark money’ group: KFF
- 10 federal government, policy updates for dentists to know
- The highest-paid ophthalmologist in the 10 largest Northeastern cities
- Arizona cardiology group pays $4.75M to settle false claims allegations
- Why AI is keeping dental practice owners up at night
- OSF HealthCare uses text outreach after ED visits — and sees 33% engagement
- Medicare spending on ASCs jumps 16% in 1 year: MedPAC
- The uneven competition in physician markets
- ‘Dark Money’ Group Angles for Higher Medicare Advantage Payments
- Judge grants Mississippi hospital pause on Medicaid debt repayment
- Inside the erosion of independence in cardiology
- OIG green-lights ASC cataract supply discount proposal
- Children’s Hospital of Philadelphia anesthesiologist receives lifetime achievement award
- Oceans Behavioral Hospital debuts virtual outpatient program
- UF Health opens 24K-square-foot orthopedic surgical center
- Illinois health association to open $4M dental practice
- 30+ dental industry updates in California, Florida and Texas
- Heartland Dental expands in 4 states
- Crestwood Behavioral Health names program chief
- Dartmouth hospital launches social work department
- Georgia health system launches new digital patient billing system
- 5 DSOs making headlines
- Oceans behavioral health hospital taps CEO
- Amazon launches health AI agent on its website, expands free virtual care to 200M Prime members
- Pediatric dental, orthodontic practice building sold for $4.4M
- San Francisco secures $100M to expand behavioral health treatment to 3 sites
- How nursing backgrounds shaped 2 revenue cycle leaders
- Study Finds 'Forever Chemicals' on California Fruits and Vegetables
- Bad News for Multitaskers: Your Brain Can’t Really Do It
- OSF HealthCare uses digital therapeutics to create a digital path to care
- Former Tenet CFO joins Acadia Healthcare board
- About 3,000 Wayfair Dressers Recalled Over Child Tip-Over Risk
- Microsoft Unveils AI Health Tool That Can Read Your Medical Records
- FDA Town Hall: FDA’s Quality Management System Regulation (QMSR) – Medical Device Risk-Based Inspections
- FDA Town Hall: FDA’s Quality Management System Regulation (QMSR) – Medical Device Risk-Based Inspections
- The feds will overpay Medicare Advantage plans by $76B this year, MedPAC estimates
- FDA Launches New Adverse Event Look-Up Tool
- FDA Launches New Adverse Event Look-Up Tool
- FDA Issues Final Guidance on Medical Devices with Indications Associated with Weight Loss
- FDA Issues Final Guidance on Medical Devices with Indications Associated with Weight Loss
- The 510(k) Pathway in 2026: Navigating a Shifting Regulatory and Political Landscape for Medical Devices
- The 510(k) Pathway in 2026: Navigating a Shifting Regulatory and Political Landscape for Medical Devices
- Bayer found to have discredited pharma industry after Roche row
- Industry Voices—Fast answers, fragile data: the trust problem in AI-driven healthcare analytics
- Pfizer CEO Albert Bourla collects $27.6M in 2025 pay following Metsera, MFN deals
- GSK catches up to Pfizer, Moderna with FDA expansion for Arexvy
- Experts Weigh in on Digital Health Wearables for Neurological Health
- Ultra-Processed Foods Bad For Bone Health, Researchers Say
- AI-Generated Meal Plans For Dieting Teens Could Be Harmful, Study Warns
- Fertility Treatments Aren't Linked To Added Cancer Risk For Women, Study Concludes
- There's One Simple Way Cancer Patients Can Ward Off 'Chemo Brain,' Study Finds
- Younger Stroke Survivors Face Unique Mental Health Hurdles
- 'Manufacturing is access': How Gilead's early production moves set PrEP med Yeztugo up for success
- Families Scramble To Pay Five-Figure Bills as Clock Ticks on Promised Preauthorization Reforms
- Medicare Advantage ‘Dark Money’ Group Attempts To Win Higher Payments for Insurance Companies
- Doctors Warn of a Deadly Complication From Measles Outbreaks
- FDA scolds CDMO Simtra with warning letter over contamination fumbles
- FDA fires off another manufacturing-related CRL, this one to Hyloris
- Hospital margins take a dive
- Florida woman accused of operating illegal dental clinic out of home
- North Carolina updates mental health bed registry
- Medicare Advantage spending 14% higher than fee for service: Report
- Washington hospital to close pediatric rehab clinic
- New Jersey system partners with health center ahead of ED closure
- What the Health? From KFF Health News: RFK Jr.’s Very Bad Week
- Report on doctor's sexual abuse spurs promises of structural change at Columbia. Survivors say it isn't enough
- Dana-Farber boosts operating margin to 8.4% in Q1
- Fierce Pharma Asia—A trio of Lilly investments; Pfizer, Sciwind's GLP-1 nod; Astellas' MFN windfall
- Remarks at the Investor Advisory Committee Meeting
- Pediatric Allergy Specialist: Feed Babies Allergenic Foods Earlier, Not Later
- FDA Warns Novo Nordisk Broke Safety Reporting Rules
- Doctors Warn Patients to Research Cosmetic Surgery Providers Before Getting Work Done
- Adam’s Lib: Remarks at the Meeting of the SEC Investor Advisory Committee
- Remarks for the Investor Advisory Committee Meeting
- Gallup poll: One in three Americans cutting back on daily expenses to pay for healthcare
- AMA: Physicians' use of AI doubled from 2023 to 2026
- Study Suggests Epilepsy Drug Sulthiame May Help Treat Sleep Apnea
- At HIMSS26, Dr. Oz, CMS officials push agentic AI adoption. Are Medicare beneficiaries ready?
- Stryker Cyber Attack Being Reported as Iranian War Retaliation
- Stryker Cyber Attack Being Reported as Iranian War Retaliation
- After China outlay, Lilly plugs $126M into Japan manufacturing plant expansion
- Legend remains bullish on Carvykti growth despite threat from J&J’s Tecvayli
- FDA rolls out new streamlined adverse event monitoring system, eyes $120M in savings
- Eisai chooses 'Pokémon Sleep' app to battle bad sleep habits in awareness campaign
- Electrodes Partially Restore Movement, Sensation In Spinal Cord Patients
- Genetic Test May Predict Leukemia Relapse Risk
- Switching GLP-1 Medications Is Common, Can Help People Stick With Weight-Loss Treatment
- Millions Of Americans Making Financial Sacrifices To Afford Health Care, Survey Finds
- More Concussions Linked To Worse Brain Health Among Recent College Grads
- Years of Specialized Support Essential with Rare Heart Defects
- In latest compounding clash, Lilly flags high levels of 'impurity' in tirzepatide knockoffs with vitamin B12
- New Medicaid-focused doula provider Malama launches with $9.2M
- Republicans Fret Over RFK Jr.’s Anti-Vaccine Policies While MAHA Moms Stew
- As Lung Disease Threatens Workers, Lawmakers Seek Protections for Countertop Manufacturers
- Rare disease drug sales to surge past $400B by 2032 despite FDA volatility: Evaluate report
- Microsoft unveils Copilot Health as an AI health companion for consumers
- HIMSS26: HHS officials offer updates on interoperability efforts, information blocking enforcement
- Despite insurers' expense pains, Tenet Healthcare is securing healthy commercial rates through 2027
- Study Links State Taxes to COVID Lockdown Decisions
- Aetna to pay $117.7M to settle Medicare Advantage upcoding allegations: DOJ
- UPDATED: Stryker hit by international cyberattack linked to pro-Iran group
- AHA: Hospitals' total expenses rose by 7.5% in 2025
- AstraZeneca recruits Joshua Jackson, Philadelphia Flyers' Gritty to cancer screening push
- As Lilly flourishes in Q4, peer projections signal looming sector slowdown in 2026
- FDA May Allow Some Flavored Vapes Aimed at Adults
- Dark Sweet Cherries May Help Slow Aggressive Breast Cancer, Mouse Study Suggests
- FDA Approves Leucovorin for Rare Brain Disorder, Not Autism
- Joint Economic Committee report: Medicare Advantage overpayments drive up Part B premiums
- Veeva shells out $100M for Ostro and its AI chat tool for pharma brand engagement
- Lilly beefs up oral GLP-1 capacity with $3B manufacturing pledge in China
- UCB's Bimzelx continues winning streak with victory over AbbVie's Skyrizi
- Lowering Parents' Stress Can Reduce Risk Of Childhood Obesity
- Multilingualism Might Not Aid Brain Aging, Researcher Argues
- 15-Year Study Shows Sharp Rise in Depression Among U.S. College Students
- Repealing Motorcycle Helmet Laws Leads to More Severe Crashes, Millions in Added Treatment Costs
- Why Childhood Cavities May Predict Adult Heart Disease
- Physical Therapy Costs Vary Widely In U.S., Study Finds
- J&J's Joaquin Duato joins $30M CEO pay club with 30% compensation boost for 2025
- Cosmetic Surgery Investigation Prompts Warnings for Patients, and a Push for Tighter Safety Standards
- Primary Care Is in Trouble. So Doctors Band Together To Boost Their Market Power.
- Skyhawk taps Teva alum to steer commercial path, while Santhera names new CCO to grow DMD sales
- Driving the news at HIMSS26: Verily, Samsung ink collaboration; Meditech's latest AI solutions
- Remarks at the Institute of International Bankers 2026 Annual Washington Conference
- Fostering Regulatory Harmony Between the SEC and CFTC
- Here's where hospital markets are the most concentrated
- A look at how CVS is leaning on 'agentic twins' in developing consumer tech
- Patent expirations push biopharma industry toward a tougher 2026
- Sandoz to set up standalone biosimilars unit as it eyes upcoming 'golden decade' of patent losses
- AbbVie's Robert Michael earns hefty pay bump to $32.5M in 2nd year as CEO
- NYU Stern report calls for private equity reforms to safeguard quality of care
- Remarks at the International Bar Association’s 24th Annual International Conference on Private Investment Funds
An Ohio telehealth company called Hims and Hers Health introduced a compounded, $ 49 per month GLP-1 agonist pill to the market yesterday and chaos has reigned in the pharmaceutical space ever since:
Exclusive: Hims offers cheapest GLP-1 weight-loss pill in US in a shock to Novo, Lilly
By Amina Niasse - February 5, 2026Summary
- Hims and Hers Health will offer the drugs at a price $100 cheaper than the brand-name offerings
- Novo Nordisk shares fall to lowest level since 2021
- Novo says it is considering legal action
NEW YORK, Feb 5 (Reuters) - Online telehealth company Hims and Hers Health (HIMS.N) on Thursday began offering a much cheaper $49 compounded version of Novo Nordisk's (NOVOb.CO) new Wegovy weight-loss pill in a move that expands sales to many Americans but could undercut Novo's and Eli Lilly's (LLY.N) plans for the consumer market.
The news touched off a swift reaction on Wall Street as investors sold off Novo and Lilly shares, and the Danish drugmaker promised a legal challenge to the move by Hims. Novo shares fell 8.6%, while Lilly was off (LLY.N) 6%.
Hims' pricing, $49 for the first month and $99 afterwards for those who purchase a five-month plan, makes their GLP-1 drug as affordable as monthly internet or streaming services in the U.S. It can offer access to treatment for many more of the estimated 200 million Americans who are overweight or obese.
It is $100 less than Novo, which launched its pill in January at $149 for first-time users and $199 after that. Lilly is expected to launch its pill in April and has promised the Trump Administration affordable pricing including on its new TrumpRx site.
Hims' move came after Novo warned on Wednesday that pricing pressure was unprecedented for its weight-loss medicines and dropped its full-year forecast. Novo shares on Thursday hit their lowest level since July 2021.
NOVO SAYS ITS PILL IS UNIQUE
Novo CEO Mike Doustdar in a meeting with investors on Thursday said people spending $49 on a Hims' pill would be wasting their money and that Novo's pill uses unique technology that aids in the absorption of the medicine.
Novo spokeswoman Ambre James-Brown described Hims' mass compounding as illegal. "Novo Nordisk will take legal and regulatory action to protect patients, our intellectual property and the integrity of the U.S. gold-standard drug approval framework," she said.
A Hims spokesperson said it has not compromised on safety or efficacy and that the company uses a technology based on liposomes that is intended to support absorption.
Analysts questioned if customers would get similar results on the cheaper pill but said it could drive a price war if compounders can provide an oral drug in large quantities.
Hims has been tussling with Novo since it was allowed in 2023 by the U.S. Food and Drug Administration to sell versions of Novo's GLP-1 injectible drugs while the branded medicines were in short supply. Since then, it has made "personalized" copies of the branded drugs at different doses or regimens than those available from Novo and other drug companies.
These drugs are not FDA approved and are subject to limited agency oversight. They also do not go through clinical trials to prove efficacy. Novo's Wegovy pill showed weight loss of more than 16% in trials.
"The status quo for months now has been a compounder can create a copycat version of a branded drug, so long as they make some kind of minor tweak that they believe or they argue benefits specific patient groups," said TD Cowen analyst Michael Nedelcovych.
HIMS MAKES CASE FOR MORE CHOICE
Hims said the treatment can be tailored for patients aiming to mitigate side effects or who prefer a pill over the injectable option. Semaglutide is the main ingredient in the new Wegovy pill as well as injectable Wegovy and Ozempic.
"We're excited to find ways to continue bringing branded treatments to the platform across specialties. More choice on the platform is the best thing for customers everywhere," said Hims CEO Andrew Dudum in a statement.
Novo and Hims had a partnership in 2025 allowing the telehealth company to offer injectable Wegovy, but the two companies walked away with Novo saying Hims had wrongfully marketed versions of its medicine. Dudum accused Novo of attempting to control how clinicians at Hims make decisions.
By tailoring its offering for patients with side effects or an aversion to needles, Gaston Kroub, a patent lawyer in New York, said Hims is positioning the oral product as another personalized option, widening the scope of personalization under the FDA’s framework.
"HIMS has shown a willingness to go as close to the line as possible,” he said. “It’s a strategy of saying, ‘All right, if we pop our head over the barbed wire fence, is anybody going to take a shot?’”
Novo launched the drug in the beginning of January and has seen strong demand in the U.S., where it is available on its cash-pay direct-to-consumer website.
Novo Chief Financial Officer Karsten Munk Knudsen told Reuters on Wednesday that the drugmaker is frustrated by continued mass marketing of compounded drugs, and said it was up to the U.S. regulator and politicians to address this.
The FDA in September issued a warning to Hims regarding its marketing of compounded semaglutide, stating claims like "same active ingredient as Ozempic and Wegovy" are misleading, as compounded drugs are not FDA-approved.
LILLY PILL IS NEXT UP
In addition to U.S. pricing pressure, Novo is girding for competition from Eli Lilly on the oral weight-loss front as the Indianapolis-based drugmaker expects to launch its own pill in the second quarter.
Some analysts said Lilly's pill, an experimental GLP-1, could be a next target for compounded copies. Compounding, in which pharmacies mix ingredients for specialized medicines or to copy a drug but at different dosages, has flourished as Americans chase cheaper prices for drugs.
Hims declined to comment on the drug. Lilly did not have an immediate comment.
In 2025, Hims doubled the size of its facility in New Albany, Ohio. The company said on Thursday the expansion allows Hims to provide treatments at a lower price.
In response to the Hims and Hers Health GLP-1 receptor agonist pill offering, FDA Commissioner Marty Makary says that the Food and Drug Administration will "take swift action" against companies mass-marketing illegal copycat drugs. Uppermost on his mind is undoubtedly the New England Compounding Center (NECC) in Framingham, Massachusetts whose contaminated injectable epidural steroids caused a fungal meningitis outbreak in 2012 which killed more than 64 people, including 11 here in Michigan:
Novo Nordisk shares rebound as FDA targets illegal drug copies
By Jacob Gronholt-Pedersen - February 6, 2026COPENHAGEN, Feb 6 (Reuters) - Shares in Danish drugmaker Novo Nordisk (NOVOb.CO) gained 5.4% on Friday, recovering some of the previous two sessions' steep losses, after the U.S. Food and Drug Administration (FDA) pledged to address mass-marketing of unapproved drugs.
The stock plunged nearly 8% on Thursday after telehealth company Hims and Hers Health (HIMS.N) launched a significantly cheaper $49 compounded version of Novo Nordisk's FDA-approved Wegovy weight-loss pill.
Novo's shares, which are near their lowest since Wegovy was introduced in June 2021, were 5.4% higher at 1341 GMT.
Late on Thursday, FDA Commissioner Marty Makary said on X that the agency would "take swift action" against companies mass-marketing illegal copycat drugs. "The FDA cannot verify the quality, safety or effectiveness of non-approved drugs," he said without naming any companies.
Despite the FDA statement, Bernstein analyst Christian Moore said he wasn't holding his breath for U.S. authorities to take decisive action.
"We do think people will still buy it, and don’t think the government will do anything to stop it, based on precedent," he said.
The FDA and individual states share regulatory authority over compounding pharmacies. In September, it launched a new tracker to show when ingredients were coming from FDA-inspected facilities. It also sent letters that month to companies it said were practicing deceptive direct-to-consumer advertising, including Hims, Novo, and rival Eli Lilly (LLY.N).
Novo, which on Wednesday flagged unprecedented price pressure that saw its stock plunge 17%, said on Thursday it would take "legal and regulatory action" in response to Hims' announcement but declined to elaborate further on Friday.
Eli Lilly, which is awaiting a U.S. regulatory decision on its weight-loss pill orforglipron, was also critical of the launch announcement.
"Patients deserve better than untested knockoffs that are sold without clinical evidence that they even work," a Lilly spokesperson said in an email to Reuters on Thursday before Makary's public post.A Hims spokesperson said on Thursday the company had not compromised on safety or efficacy and used a technology based on liposomes intended to support absorption, in response to similar criticisms from Novo.
Lilly's shares, which had ended the prior session down about 8%, rose 3.8% in premarket trading.
($1 = 6.3327 Danish crowns)
Hims & Hers Health folds:
https://x.com/HimsHersComms/status/2020207947645911214
PostHims & Hers Comms
@HimsHersCommsSince launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment. We remain committed to the millions of Americans who depend on us for access to safe, affordable, and personalized care.
This may change in March, when Novo Nordisk's compound patent expires.
Novo Nordisk filed suit against Hims & Hers:
Novo Nordisk sues Hims & Hers over patent infringement
By Stine Jacobsen - February 9, 2026COPENHAGEN, Feb 9 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Monday it has filed a lawsuit against U.S. telehealth company Hims & Hers (HIMS.N), opens new tab for infringing on the Danish group's patents.
"Novo Nordisk is asking the court to permanently ban Hims from selling unapproved, compounded drugs that infringe our patents, and is seeking to recover damages," the Danish drugmaker said in a statement.
The move comes after Hims on Saturday cancelled the launch of a $49 copy of a weight-loss pill from Novo Nordisk and the U.S. Food and Drug Administration.
The Hims and Hers' reply:
https://x.com/HimsHersComms/status/2020854864666923411
PostHims & Hers Comms
@HimsHersCommsNovo Nordisk’s lawsuit is a blatant attack by a Danish company on millions of Americans who rely on compounded medications for access to personalized care. Once again, Big Pharma is weaponizing the US judicial system to limit consumer choice. This lawsuit attacks more than just one medication or company – it directly assaults a well-established, vital component of US pharmacy practice that has improved patient care for everything from obesity to infertility to cancer. Hims & Hers has a long history of providing safe access to personalized healthcare to millions of Americans, and we will continue to fight to provide choice, affordability, and access.
8:38 AM · February 9, 2026
Hims & Hers Health falls on its financial sword:
Hims & Hers forecasts first-quarter sales below estimates, shares fall
By Sneha S K in Bengaluru; Editing by Alan Barona - February 23, 2026Summary
- Shares fall 7% after hours
- Personalized weight-loss products generate $65 million headwind in Q1
- Overseas expansion to boost growth in non-weight-loss business
Feb 23 (Reuters) - Online telehealth company Hims & Hers Health (HIMS.N), which sells weight-loss drugs, hormone replacement therapies and health services, on Monday forecast first-quarter revenue below estimates, pushing its shares down 7% in after-hours trading.
The company said that the first quarter would be facing a $65 million burden from changes in the shipping of weight-loss products, which must be personalized for each prescription based on U.S. law.
Hims and Hers has grown rapidly as customers flocked to its cheap weight-loss drugs, which include compounded injectable versions of Novo Nordisk's highly popular Wegovy. Since those drugs are no longer in shortage, Hims is only allowed to make the medicines for customers if the dosage or ingredients are personalized.
Hims' efforts to launch compounded copies of Novo's new Wegovy pill at an introductory price of $49 per month were cut down earlier this month by the U.S. Food and Drug Administration, which said it would take action against it and other companies and referred Hims to the Department of Justice. Hims said in a regulatory filing that it is unclear what actions the regulators and DOJ may pursue. Novo also filed a patent suit against the company.
The stock is down 52% so far this year. Still, the company gave a 2026 outlook with the midpoint above analysts' estimates and vowed to stay on course.
"We plan to continue to operate like we always have," said CEO Andrew Dudum, who added the company is systematically broadening and diversifying its offerings. "It's important to remember that the majority of our revenue and profitability is driven by offerings outside of weight loss."
Hims and Hers forecast revenue of $600 million to $625 million for the first quarter, missing estimates of $653.11 million, according to data compiled by LSEG.
Hims also expects 2026 revenue to be in the range of $2.7 billion to $2.9 billion, compared to estimates of $2.74 billion.
REGULATORY RISK FUELS UNCERTAINTY
International expansion may help it grow but does not address the continuity of the company's weight-loss business, which remains uncertain due to regulatory risks, said Michael Cherny, an analyst at Leerink Partners.
"It would widen the long-term opportunity, but the more important component for the stock is how Hims progresses with its weight-loss business," Cherny said.
The company said its outlook gives "flexibility to lean into future investments" and said it will keep Hims on track for its 2030 target of more than $6.5 billion in revenue.
Hims last week said it will acquire Australian digital health company Eucalyptus in a deal valued at up to $1.15 billion. Analysts said the deal could accelerate growth for the company's non-weight-loss offerings.
Subscribers rose to 2.5 million, up 13% from the prior year.
It reported quarterly revenue of $617.8 million, an increase of 28% year-over-year, but below the analysts' average estimate of $619.22 million.
The company's product costs increased over 30%, a regulatory filing showed.
Hims' investment in its Super Bowl ad will also raise first-quarter operating costs, CFO Yemi Okupe said.
Novo Nordisk A/S and Hims & Hers Health Inc. have kissed and made up. Novo and Hims will announce a new partnership to sell GLP-1 receptor agonist drugs Monday:
Novo and Hims to sell obesity drugs together as feud ends, Bloomberg News reports
By Carlos Méndez in Mexico City and Mihika Sharma in Bengaluru - March 6, 2026March 6 (Reuters) - Wegovy maker Novo Nordisk (NOVOb.CO), opens new tab plans to sell its weight-loss drugs on Hims & Hers Health (HIMS.N), opens new tab platform, bringing an end to a dispute between the two companies that escalated into a legal battle last month, Bloomberg News reported on Friday.
Hims shares surged 39% in after-hours trading after the report.
The report comes nearly a month after Novo sued Hims over patent infringement following the U.S. telehealth firm's launch, and then cancellation, of a $49 copy of Novo's obesity pill.
The U.S. Food and Drug Administration had also threatened action against Hims.
Novo and Hims plan to announce a new partnership as soon as Monday, the report said, citing a person familiar with the matter.
Last year, Novo ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims over the company's marketing tactics and continued sales of Wegovy copies.
A Novo spokesperson said in an e-mailed statement the company is "always in conversation with companies that can help improve patient access to FDA-approved medicines".
Hims did not immediately respond to a request for comment.
The power of the greenback on full display! 😍
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.
Sponsors
Friends of MHF
Kirsten DeVries
Tom & Karen Nunheimer
Steve Ahonen
Ron & Faith Bosserman
Marlin & Kathy Klumpp
Sign Up for MHF Insights to keep up on the latest in Michigan Health Policy
